Suppr超能文献

细菌脂肪酸合成是否是抗菌药物发现的有效靶点?

Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

机构信息

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, United States.

出版信息

Curr Opin Microbiol. 2011 Oct;14(5):544-9. doi: 10.1016/j.mib.2011.07.029. Epub 2011 Aug 20.

Abstract

The emergence of resistance against most current drugs emphasizes the need to develop new approaches to control bacterial pathogens, particularly Staphylococcus aureus. Bacterial fatty acid synthesis is one such target that is being actively pursued by several research groups to develop anti-Staphylococcal agents. Recently, the wisdom of this approach has been challenged based on the ability of a Gram-positive bacterium to incorporate extracellular fatty acids and thus circumvent the inhibition of de novo fatty acid synthesis. The generality of this conclusion has been challenged, and there is enough diversity in the enzymes and regulation of fatty acid synthesis in bacteria to conclude that there is not a single organism that can be considered typical and representative of bacteria as a whole. We are left without a clear resolution to this ongoing debate and await new basic research to define the pathways for fatty acid uptake and that determine the biochemical and genetic mechanisms for the regulation of fatty acid synthesis in Gram-positive bacteria. These crucial experiments will determine whether diversity in the control of this important pathway accounts for the apparently different responses of Gram-positive bacteria to the inhibition of de novo fatty acid synthesis in presence of extracellular fatty acid supplements.

摘要

耐药性的出现凸显了开发新方法来控制细菌病原体(尤其是金黄色葡萄球菌)的必要性。细菌脂肪酸合成是一个备受关注的目标,多个研究小组正在积极研究开发抗金葡菌药物。最近,由于革兰氏阳性菌能够摄取细胞外脂肪酸并因此规避从头合成脂肪酸的抑制,这种方法的有效性受到了质疑。这一结论的普遍性受到了挑战,而且细菌脂肪酸合成的酶和调控存在足够的多样性,足以得出没有一种细菌可以被视为整个细菌的典型代表的结论。对于这一持续存在的争论,我们没有明确的解决方案,只能等待新的基础研究来确定脂肪酸摄取途径,并确定革兰氏阳性菌脂肪酸合成调控的生化和遗传机制。这些关键实验将决定对这条重要途径的控制的多样性是否可以解释革兰氏阳性菌在存在细胞外脂肪酸补充时对从头合成脂肪酸抑制的反应为何不同。

相似文献

5
Bacterial fatty acid metabolism in modern antibiotic discovery.细菌脂肪酸代谢与现代抗生素发现。
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Nov;1862(11):1300-1309. doi: 10.1016/j.bbalip.2016.09.014. Epub 2016 Sep 23.
6
Essentiality of FASII pathway for Staphylococcus aureus.金黄色葡萄球菌 FASII 途径的必需性。
Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.

引用本文的文献

1
Chemical strategies for targeting lipid pathways in bacterial pathogens.针对细菌病原体脂质途径的化学策略。
Curr Opin Chem Biol. 2025 Jun;86:102596. doi: 10.1016/j.cbpa.2025.102596. Epub 2025 Apr 19.

本文引用的文献

4
Essentiality of FASII pathway for Staphylococcus aureus.金黄色葡萄球菌 FASII 途径的必需性。
Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.
9
Vinaxanthone, a new FabI inhibitor from Penicillium sp.来自青霉菌的新型FabI抑制剂——紫黄双醌
J Antimicrob Chemother. 2009 May;63(5):949-53. doi: 10.1093/jac/dkp058. Epub 2009 Mar 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验